Free Trial

Wesbanco Bank Inc. Increases Stake in GRAIL, Inc. $GRAL

GRAIL logo with Medical background

Key Points

  • Wesbanco Bank Inc. increased its stake in GRAIL, Inc. by 39.1% in Q2, owning 44,500 shares worth approximately $2.29 million.
  • GRAIL, Inc. reported a quarterly loss of ($3.18) EPS, which was slightly below analysts' expectations, with revenue at $35.54 million against a forecast of $37.57 million.
  • Insider trading activity included President Joshua J. Ofman selling 9,692 shares for $503,984, marking a 1.93% decrease in his holdings in the company.
  • MarketBeat previews top five stocks to own in October.

Wesbanco Bank Inc. grew its position in shares of GRAIL, Inc. (NASDAQ:GRAL - Free Report) by 39.1% in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 44,500 shares of the company's stock after buying an additional 12,500 shares during the quarter. Wesbanco Bank Inc. owned 0.12% of GRAIL worth $2,288,000 as of its most recent filing with the SEC.

Other large investors also recently bought and sold shares of the company. Caldwell Sutter Capital Inc. purchased a new position in GRAIL during the 1st quarter worth $28,000. KBC Group NV raised its position in GRAIL by 187.7% during the 1st quarter. KBC Group NV now owns 1,430 shares of the company's stock worth $37,000 after buying an additional 933 shares during the last quarter. S.A. Mason LLC raised its position in GRAIL by 50.1% during the 1st quarter. S.A. Mason LLC now owns 1,499 shares of the company's stock worth $38,000 after buying an additional 500 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in GRAIL during the 4th quarter worth $41,000. Finally, NewEdge Advisors LLC raised its position in GRAIL by 390.3% during the 1st quarter. NewEdge Advisors LLC now owns 1,760 shares of the company's stock worth $45,000 after buying an additional 1,401 shares during the last quarter.

GRAIL Stock Performance

Shares of GRAIL stock opened at $38.04 on Monday. The company has a market cap of $1.37 billion, a P/E ratio of -2.90 and a beta of 3.20. GRAIL, Inc. has a one year low of $12.33 and a one year high of $63.99. The firm has a fifty day moving average of $35.66 and a two-hundred day moving average of $35.43.

GRAIL (NASDAQ:GRAL - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($3.18) EPS for the quarter, missing analysts' consensus estimates of ($3.14) by ($0.04). The firm had revenue of $35.54 million for the quarter, compared to analysts' expectations of $37.57 million. GRAIL had a negative return on equity of 16.64% and a negative net margin of 329.86%. As a group, equities analysts predict that GRAIL, Inc. will post -15.15 earnings per share for the current year.

Insider Activity

In other news, President Joshua J. Ofman sold 9,692 shares of the stock in a transaction dated Monday, June 30th. The shares were sold at an average price of $52.00, for a total value of $503,984.00. Following the completion of the transaction, the president owned 492,076 shares in the company, valued at $25,587,952. This trade represents a 1.93% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CFO Aaron Freidin sold 8,000 shares of the stock in a transaction dated Tuesday, July 15th. The shares were sold at an average price of $38.93, for a total transaction of $311,440.00. Following the completion of the transaction, the chief financial officer owned 286,020 shares of the company's stock, valued at $11,134,758.60. This represents a 2.72% decrease in their position. The disclosure for this sale can be found here. Insiders sold 361,694 shares of company stock worth $17,780,266 in the last 90 days.

GRAIL Profile

(Free Report)

GRAIL, Inc operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T.

Read More

Want to see what other hedge funds are holding GRAL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GRAIL, Inc. (NASDAQ:GRAL - Free Report).

Institutional Ownership by Quarter for GRAIL (NASDAQ:GRAL)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in GRAIL Right Now?

Before you consider GRAIL, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GRAIL wasn't on the list.

While GRAIL currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.